Experimental cell therapy targets tough autoimmune diseases in kids
NCT ID NCT07439029
First seen Feb 28, 2026 · Last updated Jun 10, 2026 · Updated 17 times
Summary
This early-stage study will test a new cell therapy called YTS109 in 12 children aged 5 to 18 with severe autoimmune diseases like lupus and scleroderma that haven't responded to other treatments. The therapy is given as a single IV infusion, and the main goals are to see if it is safe and if it can help control the disease. This is a first step to see if the approach works and is safe enough for further testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS (AAV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Fudan University
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.